Legal entity
All 1 tracked stories fall under one category: corporate-law. Blaize Holdings, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Pelican Way Research appears in 1 tracked Legal story from September 27, 2026.
Last mentioned: 17h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: corporate-law. Blaize Holdings, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Pelican Way Research appears in 1 tracked Legal story from September 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pelican Way Research. Shared-story counts are live from our verified record — not editorial picks.
Lead plaintiff deadline
Deadline for Blaize investors to seek the role of lead plaintiff in the federal securities class action.
Faruqi & Faruqi reminder issued
The law firm issued a press release reminding BZAI investors of the approaching lead plaintiff deadline.
Pelican Way Research report published
The report alleged a bogus NeoTensr deal, photoshopped product images, and an implausible $20 million Q4 2025 revenue contribution; Blaize's stock price fell on the news.
NeoTensr incorporated
Per the Pelican Way Research report, NeoTensr was incorporated in late December 2025 with about $2 million in startup capital.
Class period begins
Earliest date for purchases of Blaize securities eligible under the proposed class definition.
Securities class action counsel Faruqi & Faruqi LLP has flagged an October 5, 2026 deadline for Blaize Holdings investors to move for lead plaintiff in a federal securities case alleging misleading statements about deal-driven revenue. The complaint claims a NeoTensr transaction could not plausibly support $20 million in Q4 2025 revenue.
Pelican Way Research is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
